TCR Engineered T-Cell Therapy Market Report 2018: An Industry Analysis of Technologies, Pipelines, Stakeholders & Deals - ResearchAndMarkets.com

DUBLIN--()--The "TCR Engineered T-Cell Therapy 2018: An Industry Analysis of Technologies, Pipelines, Stakeholders & Deals" report has been added to ResearchAndMarkets.com's offering.

This report, "TCR Engineered T-Cell Therapy 2018: An Industry Analysis of Technologies, Pipelines, Stakeholders & Deals" published in May 2018 brings you up-to-date regarding key TCR-T players, key TCR-T technologies and product candidates, business models, deals and funding opportunities.

The report analyzes the TCR-T pipelines and stakeholders in the field, especially focused and diversified TCR-T companies and their relationship with academia and major pharma/biotech. The report highlights the value of TCR-T assets in terms of partnering economic conditions, acquisition prices and financing rounds.

T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cutting edge of adoptive T-cell therapy. Both receptors deploy T-cells to target the tumor, but CAR T-cells (CAR-T) are limited to binding to cell surface antigens, while TCR T-cells (TCR-T) recognize peptides (derived from intracellular proteins) presented on the cell surface by the major histocompatibility complex (MHC) class I.

TCR-Ts have so far operated in the shadow of CAR-Ts, but may have the advantage in solid tumors. The first approved CD19-specific CAR-Ts are indicated for hematologic malignancies, but CAR-Ts were less successful against solid tumors.

Key questions answered:

  • Which targets are chosen for development of TCR-Ts?
  • How close are neoantigen-specific TCR-Ts to the clinic?
  • Which technologies are used for generation of T-Cell Receptors?
  • Has clinical proof-of-concept been shown for any TCR-T?
  • How does the TCR-T pipeline look like?
  • What manufacturing strategies and solutions have companies chosen?
  • Are next generation TCR-Ts already in development?
  • What are the key technologies for a successful TCR-T?
  • Who are the key players in the TCR-T field?
  • How tough is competition among TCR-T developers?
  • Should companies be focused on TCR-Ts only or be diversified into various adoptive T-cell therapeutics?
  • Which technologies and assets attract licensees?
  • How is the financing situation for TCR-T?
  • What are the key success factors for TCR-Ts?

Key Topics Covered:

1 Executive Summary

2 Introduction, Overview & Background

3 Technologies
3.1 Overview & Discussion
3.2 Technologies for Discovery of Targets for TCRs
3.3 Technologies for TCR Discovery
3.4 TCR Engineered Allogeneic T-Cells
3.5 Next Generation Technologies to Improve Safety & Efficacy

4 Pipeline
4.1 Overview & Discussion
4.2 Profiles of MAGE-A Specific TCR T-Cells
4.3 Profiles of NY-ESO-1 Specific TCR T-Cells
4.4 Profiles of AFP Specific TCR T-Cells
4.5 Profiles of PRAME Specific TCR T-Cells
4.6 Profiles of WT1 Specific TCR T-Cells
4.7 Profiles of Other Target Specific TCR T-Cells
4.8 Profiles of Neoantigen Specific TCR T-Cells

5 Manufacturing

6 Companies
6.1 Company Overview & Discussion
6.2 Pure Play TCR T-Cell Companies
6.3 Profiles of Diversified Companies with TCR-T Activities
6.4 Other Companies with TCR-T Activities

7 Business Development & Financing
7.1 Role of academia for the TCR-T industry
7.2 Role of Big Pharma & Biotech for TCR-T
7.3 Technology In-Licensing Deals
7.4 Collaborative Arrangements
7.5 Acquisitions of Companies and Assets
7.6 Financing of TCR-T Companies

8 Outlook & Perspectives

9 References

Companies Mentioned

  • Adaptimmune
  • Adicet Bio
  • Aeon Therapeutics Shanghai
  • AgenTus Therapeutics
  • Alpine Immune Science
  • Atreca
  • Bellicum Pharmaceuticals
  • BioNTech
  • Bluebird bio
  • Cell Medica
  • CRISPR Therapeutics
  • Editas Medicine
  • Eureka Therapeutics
  • Gadeta
  • GlaxoSmithKline
  • Immatics
  • ImmunoCellular Therapeutics
  • Intellia Therapeutics
  • Juno Therapeutics/Celgene
  • Kite Pharma/Gilead Sciences
  • Lion TCR
  • Medigene
  • Neon Therapeutics
  • Regeneron Pharmaceuticals
  • Sangamo Therapeutics
  • Tactiva Therapeutics
  • Takara Bio
  • TC BioPharm
  • TCR2 Therapeutics
  • Tmunity Therapeutics
  • Universal Cells
  • Zelluna Immunotherapy
  • ZIOPHARM Oncology

For more information about this report visit https://www.researchandmarkets.com/research/lbzlhj/tcr_engineered?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biotechnology, Genomics

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biotechnology, Genomics